These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 21386786)

  • 1. Clinical applications of dosimetry for mIBG therapy.
    Flux GD; Chittenden SJ; Saran F; Gaze MN
    Q J Nucl Med Mol Imaging; 2011 Apr; 55(2):116-25. PubMed ID: 21386786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient dosimetry for 131I-MIBG therapy for neuroendocrine tumours based on 123I-MIBG scans.
    Monsieurs M; Brans B; Bacher K; Dierckx R; Thierens H
    Eur J Nucl Med Mol Imaging; 2002 Dec; 29(12):1581-7. PubMed ID: 12458391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosimetry in nuclear medicine therapy: what are the specifics in image quantification for dosimetry?
    Bardiès M; Buvat I
    Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):5-20. PubMed ID: 21386782
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeted radionuclide therapy for neuroendocrine tumours.
    Lewington VJ
    Endocr Relat Cancer; 2003 Dec; 10(4):497-501. PubMed ID: 14713264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
    Matthay KK; Weiss B; Villablanca JG; Maris JM; Yanik GA; Dubois SG; Stubbs J; Groshen S; Tsao-Wei D; Hawkins R; Jackson H; Goodarzian F; Daldrup-Link H; Panigrahy A; Towbin A; Shimada H; Barrett J; Lafrance N; Babich J
    J Nucl Med; 2012 Jul; 53(7):1155-63. PubMed ID: 22700000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcomes of (131)Iodine mIBG therapy in metastatic gastrointestinal pancreatic neuroendocrine tumours: single administration predicts non-responders.
    Mulholland N; Chakravartty R; Devlin L; Kalogianni E; Corcoran B; Vivian G
    Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):2002-12. PubMed ID: 26142730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan.
    Castellani MR; Chiti A; Seregni E; Bombardieri E
    Q J Nucl Med; 2000 Mar; 44(1):77-87. PubMed ID: 10932604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-body iodine-131 metaiodobenzylguanidine imaging for detection of bone metastases in patients with paraganglioma: comparison with bone scintigraphy.
    Inoue T; Yoshinaga K; Morita K; Shiga T; Kanegae K; Hirata K; Okamoto S; Tamaki N
    Ann Nucl Med; 2007 Jul; 21(5):307-10. PubMed ID: 17634850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioiodinated metaiodobenzylguanidine treatment of neuroendocrine tumors in adults.
    Postema EJ; McEwan AJ
    Cancer Biother Radiopharm; 2009 Oct; 24(5):519-25. PubMed ID: 19877881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model.
    Madsen MT; Bushnell DL; Juweid ME; Menda Y; O'Dorisio MS; O'Dorisio T; Besse IM
    J Nucl Med; 2006 Apr; 47(4):660-7. PubMed ID: 16595501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma.
    Buckley SE; Chittenden SJ; Saran FH; Meller ST; Flux GD
    J Nucl Med; 2009 Sep; 50(9):1518-24. PubMed ID: 19713562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects and safety of ¹³¹I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry.
    Yoshinaga K; Oriuchi N; Wakabayashi H; Tomiyama Y; Jinguji M; Higuchi T; Kayano D; Fukuoka M; Inaki A; Toratani A; Okamoto S; Shiga T; Ito YM; Nakajo M; Nakajo M; Kinuya S; ; ;
    Endocr J; 2014; 61(12):1171-80. PubMed ID: 25214026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 131I-MIBG Therapy in a Metastatic Small Bowel Neuroendocrine Tumor Patient Undergoing Hemodialysis.
    Rahimi B; Makis W; Riauka TA; McEwan AJ; Morrish D
    Clin Nucl Med; 2017 May; 42(5):350-353. PubMed ID: 28240668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Local delivery of (131)I-MIBG to treat peritoneal neuroblastoma.
    Kinuya S; Li XF; Yokoyama K; Mori H; Shiba K; Watanabe N; Shuke N; Bunko H; Michigishi T; Tonami N
    Eur J Nucl Med Mol Imaging; 2003 Sep; 30(9):1246-50. PubMed ID: 12811531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraarterial 131I-MIBG therapy of neuroendocrine tumors with liver metastases.
    Popp M; Strumpf A; Zöphel K; Stroszczynski C; Kotzerke J
    Nuklearmedizin; 2010; 49(1):N2-3. PubMed ID: 20336828
    [No Abstract]   [Full Text] [Related]  

  • 16. ¹¹¹In-DTPA⁰-octreotide (Octreoscan), ¹³¹I-MIBG and other agents for radionuclide therapy of NETs.
    Bomanji JB; Papathanasiou ND
    Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1():S113-25. PubMed ID: 22388626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG).
    Trieu M; DuBois SG; Pon E; Nardo L; Hawkins RA; Marachelian A; Twist CJ; Park JR; Matthay KK
    Pediatr Blood Cancer; 2016 Mar; 63(3):436-42. PubMed ID: 26506090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thyroidal uptake and radiation dose after repetitive I-131-MIBG treatments: influence of potassium iodide for thyroid blocking.
    Brans B; Monsieurs M; Laureys G; Kaufman JM; Thierens H; Dierckx RA
    Med Pediatr Oncol; 2002 Jan; 38(1):41-6. PubMed ID: 11835235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosimetric results in treatments of neuroblastoma and neuroendocrine tumors with (131)I-metaiodobenzylguanidine with implications for the activity to administer.
    Mínguez P; Flux G; Genollá J; Guayambuco S; Delgado A; Fombellida JC; Sjögreen Gleisner K
    Med Phys; 2015 Jul; 42(7):3969-78. PubMed ID: 26133597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ten years of experience with MIBG applications and the potential of new radiolabeled peptides: a personal overview and concluding remarks.
    Shapiro B
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):150-5. PubMed ID: 9002776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.